DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 12, 2006; DOI: 10.1124/dmd.105.009175


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.009175v1
34/7/1109    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishiguro, N.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishiguro, N.
Right arrow Articles by Sugiyama, Y.


Received for publication December 28, 2005.
Revised March 31, 2006.
Accepted for publication April 3, 2006.

Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans

Naoki Ishiguro 1, Kazuya Maeda 2, Wataru Kishimoto 1, Asami Saito 1, Akiko Harada 1, Thomas Ebner 3, Willy Roth 3, Takashi Igarashi 1, Yuichi Sugiyama 2*

1 Nippon Boehringer Ingelheim Co. Ltd. 2 Graduate School of Pharmaceutical Sciences, Univ. of Tokyo 3 Boehringer Ingelheim Pharma KG

* Address correspondence to: E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

Abstract

Telmisartan, a nonpeptide angiotensin II receptor antagonist, is selectively distributed to liver. In the present study, we have characterized the contribution of organic anion transporting polypeptide (OATP) isoforms to the hepatic uptake of telmisartan by isolated rat hepatocytes, human cryopreserved hepatocytes and human transporter-expressing cells. Because it is difficult to evaluate the transport activity of telmisartan due to its extensive adsorption to cells and culture materials, we performed the uptake study in the presence of human serum albumin. The saturable uptake of telmisartan into isolated rat hepatocytes took place in a Na+-independent manner and was inhibited by pravastatin, taurocholate and digoxin, which are Oatp substrates and inhibitors, but not by organic cation, tetraethylammonium, indicating the involvement of Oatp isoforms in its uptake into rat hepatocytes. To identify which human OATP transporters are important for the hepatic uptake of telmisartan, the uptake assay was carried out using OATP1B1- and OATP1B3-expressing HEK293 cells and cryopreserved human hepatocytes. The uptake of telmisartan by OATP1B3-expressing cells was saturable (Km= 0.81 µM) and significantly higher than that by vector-transfected cells. In contrast, no significant uptake was observed in OATP1B1-expressing cells. We also observed the saturable uptake of telmisartan by human hepatocytes. Thirty µM estrone-3-sulfate, which can selectively inhibit OATP1B1-mediated uptake compared with OATP1B3, did not inhibit the uptake of telmisartan in human hepatocytes, while it could inhibit the uptake of estradiol 17{beta}-D-glucuronide mediated by OATP1B1. These results suggest that OATP1B3 is predominantly involved in the hepatic uptake of telmisartan in humans.


Key words: drug distribution, hepatic transport, hepatic uptake, hepatocytes, organic anion transport, pharmacokinetics, transporters





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.